How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story
- Neurocrine Biosciences recently presented new data from its KINECT-HD2 study at the 2025 MDS International Congress, showing that INGREZZA capsules provided sustained improvements in chorea severity and maintained a well-established safety profile in adults with Huntington’s disease over three years of treatment.
- This positive long-term efficacy and safety data increases clinical confidence in INGREZZA’s role for Huntington’s disease and highlights Neurocrine’s advancing leadership in neuropsychiatric treatment options.
- We'll explore how the new INGREZZA Huntington's disease data supports Neurocrine's investment case and future neuropsychiatry franchise growth initiatives.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Neurocrine Biosciences Investment Narrative Recap
To be a shareholder in Neurocrine Biosciences, I believe you must have conviction in the company's ability to expand its neuropsychiatry leadership through sustained, long-term growth from INGREZZA and emerging therapies. The recent positive long-term Huntington’s disease data supports ongoing adoption but is unlikely to materially change the near-term focus; the most important short-term catalyst remains robust uptake and access for INGREZZA, while pricing pressures in Medicare and commercial channels continue to pose the most pressing risk to margins and revenue stability.
Among recent developments, the appointment of Mike Sibley as Senior Vice President and General Manager of the Neuropsychiatry franchise directly ties into INGREZZA's growth narrative. His 20 years of commercial experience and responsibility over sales and marketing initiatives may help strengthen positioning amid competitive threats and payer scrutiny, helping to drive franchise resilience as the company pursues key catalysts.
However, investors should be aware that, despite promising clinical milestones, pricing pressure and payer tightening could challenge even well-established product franchises like INGREZZA if...
Read the full narrative on Neurocrine Biosciences (it's free!)
Neurocrine Biosciences is projected to reach $3.8 billion in revenue and $976.5 million in earnings by 2028. This outlook is based on an assumed annual revenue growth rate of 14.6% and an increase in earnings of $628.2 million from current earnings of $348.3 million.
Uncover how Neurocrine Biosciences' forecasts yield a $168.25 fair value, a 21% upside to its current price.
Exploring Other Perspectives
Seven individual fair value estimates from the Simply Wall St Community fall between US$119 and US$314 per share. Despite this wide range of outlooks, the persistent risk of payer scrutiny and pricing pressure could shape future revenue, so consider exploring multiple viewpoints before making a decision.
Explore 7 other fair value estimates on Neurocrine Biosciences - why the stock might be worth 15% less than the current price!
Build Your Own Neurocrine Biosciences Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.
Want Some Alternatives?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Neurocrine Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com